Treating Gastrointestinal and Autism Symptoms in Adults with Autism using Microbiota Transfer Therapy (MTT)
Abstract
Purpose: The purpose of this study is to determine the safety and efficacy of Microbiota Transfer Therapy for adults with autism and chronic gastrointestinal problems. Scope: The scope of the project is a randomized, double-blind, placebo-controlled trial of MTT for 84 adults with autism. The trial also includes an extension, partial cross-over, and long-term follow-up (6, 12, and 18 months). It includes extensive evaluation of autism-related and gastrointestinal symptoms, evaluation of microbiome composition, and blood safety tests. It includes 84 neurotypical controls (half with GI symptoms, half without) for comparison of baseline microbiota (no treatment for the neurotypical group).Major findings: none to report yet.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1154868
Entities
People
- James B. Adams
- Richard E Frye
- Rosa Krajmalnik-brown
Organizations
- Arizona State University